9 hours Ago By ABMN Staff
Invesco Ltd. decreased its position in MannKind Co. ( NASDAQ:MNKD – Free Report ) by 27.
6% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,220,835 shares of the biopharmaceutical company’s stock after selling 464,293 shares during the quarter.
Invesco Ltd.’s holdings in MannKind were worth $7,850,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also added to or reduced their stakes in the company.
Jones Financial Companies Lllp boosted its position in shares of MannKind by 3,294.8% in the 4th quarter. Jones Financial Companies Lllp now owns 6,586 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 6,392 shares in the last quarter.
Beirne Wealth Consulting Services LLC bought a new stake in MannKind in the fourth quarter worth $66,000. Marshall Investment Management LLC purchased a new stake in shares of MannKind in the fourth quarter worth $69,000. Proficio Capital Partners LLC bought a new position in shares of MannKind during the fourth quarter valued at $70,000.
Finally, Los Angeles Capital Management LLC purchased a new position in shares of MannKind in the 4th quarter worth about $86,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.
MannKind Price Performance NASDAQ MNKD opened at $4.67 on Friday. MannKind Co.
has a 1-year low of $4.11 and a 1-year high of $7.63.
The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of 66.71 and a beta of 1.
22. The business’s fifty day moving average price is $5.02 and its 200-day moving average price is $5.
96. Analysts Set New Price Targets Several analysts recently commented on the stock. Mizuho started coverage on shares of MannKind in a research report on Thursday, April 10th.
They set an “outperform” rating and a $12.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $11.
00 price objective on shares of MannKind in a report on Thursday, February 27th. Finally, StockNews.com upgraded MannKind from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th.
Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $9.56.
Check Out Our Latest Research Report on MNKD MannKind Company Profile ( Free Report ) MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Featured Articles Want to see what other hedge funds are holding MNKD? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for MannKind Co. ( NASDAQ:MNKD – Free Report ). Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.
com's FREE daily email newsletter ..
